Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies

Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is a compendium of scientific articles submitted to a Special Issue of International Journal of Molecular Sciences, fostered by MDPI and curated by Dr. Annamaria Sandomenico and Dr. Menotti Ruvo from the Institute of Biostructure and Bioimaging of the National Research Council. All articles underwent a rigorous peer review and were selected to highlight the properties that make monoclonal antibodies and their functional fragments some of the most useful and versatile assets in therapy and diagnosis.

porcine deltacoronavirus --- nucleocapsid --- monoclonal antibodies --- neurodegenerative disorders --- affibody molecules --- blood–brain barrier --- receptor-mediated transcytosis --- transferrin receptor --- AL amyloidosis --- CD38 --- anti-CD38 MoAb --- Daratumumab --- Isatuximab --- myeloma --- BCMA --- bispecific T-cell engager --- antibody-drug conjugates --- chimeric antigen receptor T-cells --- belantamab mafodotin --- idecabtagene vicleucel --- JNJ-68284528 --- Mabs --- Antibody-Drug Conjugate --- cancer therapy --- drug targeting --- payload --- cross-linking --- antibody fragment --- Fab --- scFv --- E. coli --- YKL-40 --- CHI3L1 --- monoclonal antibody --- phage display --- lung metastasis --- prostate-specific membrane antigen --- in vivo imaging --- prostate cancer --- glutamate carboxypeptidase II --- NAALADase --- immunization --- antibody --- protocol --- guinea pig --- cDNA --- chimeric antigen receptor (CAR T) --- universal CAR T --- modular CAR T --- universal immune receptor --- CAR adaptor --- adoptive immunotherapy --- split CAR --- bispecific --- polyspecificity --- pharmacokinetics --- solubility --- aggregation --- viscosity --- developability --- stability --- affinity --- specificity --- protein engineering --- self-association --- non-specific binding --- immunogenicity --- antibody fragments --- single chain --- amyloid --- oligomer --- neurotoxicity --- NUsc1

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies

Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood-brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer’s and Parkinson’s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood–brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems.

Technology: general issues --- drug delivery into the brain --- transendothelium based on receptor-mediated transcytosis --- immunotherapy --- Alzheimer’s disease --- anti-tau and anti-receptor bispecific monoclonal antibodies --- Alzheimer’s disease-relevant tau species --- temporal-spatial pathological Aβ and tau distribution --- interactions between Aβ and tau --- tau clearance in microglia --- tau clearance in neurons --- liposome --- nanoparticle --- seizure --- laser --- ultrasound --- naringenin --- nanostructured lipid carrier --- intranasal delivery --- central composite rotatable design --- depression --- pomegranate seed oil --- nasal delivery system --- memory impairment --- movement impairment --- delivery to brain --- improved memory --- phospholipid oily gel --- high-grade glioma --- diffuse midline glioma --- glioblastoma --- IL-13Rα2 --- IL-13 --- immunotoxin --- targeted therapy --- GB-13 --- IL13.E13K-PE4E --- receptor expression --- acetaminophen --- blood–brain barrier --- claudin-5 --- CNS drug delivery --- opioids --- tight junction --- microdialysis --- cerebral open flow microperfusion --- electrochemical biosensors --- macromolecules --- tolcapone --- microparticles --- nanoparticles --- PLGA --- Parkinson’s disease --- nose to brain delivery --- gene therapy --- polyplexes --- hyaluronidase --- glycol chitosan --- brain cancer --- chemoattractant --- CXCL --- CXCR --- glioblastoma multiforme --- 3D cell culture systems --- non-human primate --- convection-enhanced delivery --- neurosurgery --- optogenetics --- blood-brain barrier --- brain targeted therapy --- drug delivery --- cerebrospinal fluid microcirculation --- brain biodistribution --- n/a --- Alzheimer's disease --- Alzheimer's disease-relevant tau species --- Parkinson's disease